Related Experiment Video
Updated: Dec 11, 2025

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
The C/D box small nucleolar RNA SNORD52 regulated by Upf1 facilitates Hepatocarcinogenesis by stabilizing CDK1
Cuicui Li1, Long Wu2, Pengpeng Liu2
1Department of Integrated Internal Medicine and Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan 430071, P.R. China.
Abstract:
Rationale: Understanding the roles of small nucleolar RNAs (snoRNAs) in hepatocarcinogenesis will provide new avenues to identify diagnostic and therapeutic targets for hepatocellular carcinoma (HCC). Our previous research confirmed the tumor-suppressive effect of Up-frameshift 1 (Upf1) in HCC. Herein, we examined the expression profiles of snoRNAs regulated by Upf1 in hepatoma cells. Methods: We examined the expression profiles of snoRNAs regulated by Upf1 in hepatoma cells using RNA-sequencing analysis and then investigated the expression and significance of SNORD52 in HCC tissue and different cell lines. The protumorigenic effects of SNORD52 on HCC cells were confirmed both in vitro and in vivo by gain-of-function and loss-of-function assays. RNA pull-down assays and mass spectrometry were used to identify the RNA-binding protein that binds to SNORD52. Results: Many snoRNAs were identified; one of which, the human C/D box small nucleolar RNA SNORD52, was upregulated in HCC tissues and negatively correlated with Upf1 expression, and patients with higher SNORD52 expression had a poor clinical prognosis. SNORD52 promoted HCC tumorigenesis both in vitro and in vivo. Mechanistically, KEGG analysis showed that SNORD52 upregulated a series of cell cycle genes in HCC cells. We further confirmed that SNORD52 upregulated CDK1 by enhancing the stability of CDK1 proteins and that the function of SNORD52 depends on the presence of CDK1. Conclusion: Overall, the present study indicates that SNORD52 could be a potential biomarker for HCC. Targeting the Upf1/SNORD52/CDK1 pathway might have therapeutic potential for HCC.
Insights
Small nucleolar RNA SNORD52 promotes hepatocellular carcinoma (HCC) by upregulating cell cycle genes, particularly CDK1. Targeting the Upf1/SNORD52/CDK1 pathway offers potential therapeutic strategies for HCC.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Small nucleolar RNAs (snoRNAs) play roles in hepatocarcinogenesis, offering potential diagnostic and therapeutic targets for hepatocellular carcinoma (HCC).
- Previous research established the tumor-suppressive role of Up-frameshift 1 (Upf1) in HCC.
- This study investigates snoRNAs regulated by Upf1 in hepatoma cells.
Purpose of the Study:
- To examine the expression profiles of snoRNAs regulated by Upf1 in hepatoma cells.
- To investigate the expression and significance of SNORD52 in HCC.
- To elucidate the protumorigenic mechanisms of SNORD52 in HCC.
Main Methods:
- RNA-sequencing analysis to profile snoRNAs regulated by Upf1.
- In vitro and in vivo gain- and loss-of-function assays to assess SNORD52's role in HCC.
- RNA pull-down assays and mass spectrometry to identify SNORD52-binding proteins.
Main Results:
- SNORD52, a C/D box small nucleolar RNA, was upregulated in HCC tissues and negatively correlated with Upf1 expression.
- Higher SNORD52 expression correlated with poor clinical prognosis in HCC patients.
- SNORD52 promoted HCC tumorigenesis by upregulating cell cycle genes, specifically enhancing CDK1 protein stability.
Conclusions:
- SNORD52 is a potential biomarker for hepatocellular carcinoma.
- The Upf1/SNORD52/CDK1 pathway presents a potential therapeutic target for HCC treatment.
Related Concept Videos
Inhibition of Cdk Activity
Negative Regulator Molecules
Regulation of Nuclear Protein Sorting
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
Anaphase Promoting Complex

